77 related articles for article (PubMed ID: 9167836)
1. Tardive dyskinesia and ethnicity: review of the literature.
Swartz JR; Burgoyne K; Smith M; Gadasally R; Ananth J; Ananth K
Ann Clin Psychiatry; 1997 Mar; 9(1):53-9. PubMed ID: 9167836
[TBL] [Abstract][Full Text] [Related]
2. Preventing neuroleptic-induced tardive dyskinesia in adults and children.
Lam RW; Jeste SD; Jeste DV
Encephale; 1988 Sep; 14 Spec No():251-5. PubMed ID: 2905652
[TBL] [Abstract][Full Text] [Related]
3. Cebus apella, a nonhuman primate highly susceptible to neuroleptic side effects, carries the GLY9 dopamine receptor D3 associated with tardive dyskinesia in humans.
Werge T; Elbaek Z; Andersen MB; Lundbaek JA; Rasmussen HB
Pharmacogenomics J; 2003; 3(2):97-100. PubMed ID: 12746734
[TBL] [Abstract][Full Text] [Related]
4. Lack of association between serotonin-2A receptor gene (HTR2A) polymorphisms and tardive dyskinesia in schizophrenia.
Basile VS; Ozdemir V; Masellis M; Meltzer HY; Lieberman JA; Potkin SG; Macciardi FM; Petronis A; Kennedy JL
Mol Psychiatry; 2001 Mar; 6(2):230-4. PubMed ID: 11317228
[TBL] [Abstract][Full Text] [Related]
5. CYP2D6 polymorphism and tardive dyskinesia in schizophrenic patients.
Lohmann PL; Bagli M; Krauss H; Müller DJ; Schulze TG; Fangerau H; Ludwig M; Barkow K; Held T; Heun R; Maier W; Rietschel M; Rao ML
Pharmacopsychiatry; 2003; 36(2):73-8. PubMed ID: 12734765
[TBL] [Abstract][Full Text] [Related]
6. Association study between glutathione S-transferase GST-M1, GST-T1, and GST-P1 polymorphisms and tardive dyskinesia.
Kang SG; Lee HJ; Choi JE; An H; Rhee M; Kim L
Hum Psychopharmacol; 2009 Jan; 24(1):55-60. PubMed ID: 19051221
[TBL] [Abstract][Full Text] [Related]
7. [Pharmacogenetic assessment of antipsychotic-induced tardive dyskinesia: contribution of 5-hydroxytryptamine 2C receptor gene and of a combination of dopamine D3 variant allele (Gly) and MnSOD wild allele (Val)].
Zhang Z; Hou G; Zhang X; Yao H; Sha W; Zhang X
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2003 Apr; 20(2):98-102. PubMed ID: 12673575
[TBL] [Abstract][Full Text] [Related]
8. Association of CYP2D6 and CYP1A2 gene polymorphism with tardive dyskinesia in Chinese schizophrenic patients.
Fu Y; Fan CH; Deng HH; Hu SH; Lv DP; Li LH; Wang JJ; Lu XQ
Acta Pharmacol Sin; 2006 Mar; 27(3):328-32. PubMed ID: 16490169
[TBL] [Abstract][Full Text] [Related]
9. No association between dopamine D4 receptor gene -521 C/T polymorphism and tardive dyskinesia in schizophrenia.
Lee HJ; Kang SG; Choi JE; Paik JW; Kim YK; Kim SH; Lee MS; Joe SH; Jung IK; Kim L
Neuropsychobiology; 2007; 55(1):47-51. PubMed ID: 17556853
[TBL] [Abstract][Full Text] [Related]
10. Clinical and familial correlates of tardive dyskinesia in India and Israel.
Bhatia T; Sabeeha MR; Shriharsh V; Garg K; Segman RH; Uriel HL; Strous R; Nimgaonkar VL; Bernard L; Deshpande SN
J Postgrad Med; 2004; 50(3):167-72; discussion 172. PubMed ID: 15377799
[TBL] [Abstract][Full Text] [Related]
11. Pathway-based association analysis of genome-wide screening data suggest that genes associated with the gamma-aminobutyric acid receptor signaling pathway are involved in neuroleptic-induced, treatment-resistant tardive dyskinesia.
Inada T; Koga M; Ishiguro H; Horiuchi Y; Syu A; Yoshio T; Takahashi N; Ozaki N; Arinami T
Pharmacogenet Genomics; 2008 Apr; 18(4):317-23. PubMed ID: 18334916
[TBL] [Abstract][Full Text] [Related]
12. [Manganese superoxide dismutase gene (MnSOD) polimorphism in schizophrenics with tardive dyskinesia from central Poland].
Gałecki P; Pietras T; Szemraj J
Psychiatr Pol; 2006; 40(5):937-48. PubMed ID: 17217237
[TBL] [Abstract][Full Text] [Related]
13. Tardive dyskinesia.
Soares-Weiser K; Fernandez HH
Semin Neurol; 2007 Apr; 27(2):159-69. PubMed ID: 17390261
[TBL] [Abstract][Full Text] [Related]
14. Neuroleptic medication facilitates the natural occurrence of tardive dyskinesia. A critical review.
Driesens F
Acta Psychiatr Belg; 1988; 88(3):195-205. PubMed ID: 2906780
[TBL] [Abstract][Full Text] [Related]
15. Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects: I. Association of CYP1A2 gene polymorphism.
Tiwari AK; Deshpande SN; Rao AR; Bhatia T; Mukit SR; Shriharsh V; Lerer B; Nimagaonkar VL; Thelma BK
Pharmacogenomics J; 2005; 5(1):60-9. PubMed ID: 15505641
[TBL] [Abstract][Full Text] [Related]
16. Focus on lower risk of tardive dyskinesia with atypical antipsychotics.
Nasrallah HA
Ann Clin Psychiatry; 2006; 18(1):57-62. PubMed ID: 16517454
[TBL] [Abstract][Full Text] [Related]
17. [Tardive dyskinesia: a review].
Crespo Facorro B; Payá González B; Ruiz Fernández V; Carbonell Masia C
Actas Luso Esp Neurol Psiquiatr Cienc Afines; 1997; 25(2):118-27. PubMed ID: 9245189
[TBL] [Abstract][Full Text] [Related]
18. Dogma disputed: is tardive dyskinesia due to postsynaptic dopamine receptor supersensitivity?
Jeste DV; Wyatt RJ
J Clin Psychiatry; 1981 Dec; 42(12):455-7. PubMed ID: 6118358
[TBL] [Abstract][Full Text] [Related]
19. Association study between a functional glutathione S-transferase (GSTP1) gene polymorphism (Ile105Val) and tardive dyskinesia.
Shinkai T; De Luca V; Hwang R; Matsumoto C; Hori H; Ohmori O; Remington G; Meltzer HY; Lieberman JA; Potkin SG; Nakamura J; Kennedy JL
Neurosci Lett; 2005 Nov; 388(2):116-20. PubMed ID: 16039055
[TBL] [Abstract][Full Text] [Related]
20. Haplotype analysis of endothelial nitric oxide synthase (NOS3) genetic variants and tardive dyskinesia in patients with schizophrenia.
Liou YJ; Lai IC; Lin MW; Bai YM; Lin CC; Liao DL; Chen JY; Lin CY; Wang YC
Pharmacogenet Genomics; 2006 Mar; 16(3):151-7. PubMed ID: 16495774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
